Document is current
Any future updates will be listed below
-
Authors
Francis, Luc https://orcid.org/0009-0006-2476-025X
McCluskey, Daniel
Ganier, Clarisse
Jiang, Treasa https://orcid.org/0009-0002-5786-9340
Du-Harpur, Xinyi
Gabriel, Jeyrroy https://orcid.org/0000-0003-4492-5200
Dhami, Pawan
Kamra, Yogesh
Visvanathan, Sudha
Barker, Jonathan N.
Smith, Catherine H.
Capon, Francesca https://orcid.org/0000-0003-2432-5793
Mahil, Satveer K. https://orcid.org/0000-0003-4692-3794
-
Funding
Funding for this research was provided by:
Psoriasis Association (ST2/21 RE18411)
Psoriasis Association (BSTOP50/5)
RCUK | Medical Research Council (MR/R015643/1)
RCUK | Medical Research Council (MR/W006820/1)
DH | National Institute for Health Research (guysbrc-2012-1)
DH | National Institute for Health Research (NIHR302258)
- License Information
-
More Information
Article History
Received: 27 April 2023
Accepted: 12 January 2024
First Online: 30 January 2024
Competing interests
: S.V. is a Boehringer-Ingelheim employee. J.N.B. has attended advisory boards and/or spoken at sponsored symposia and/or received research funding from: AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Samsung, Sun Pharma. C.H.S. reports departmental research funding as investigator in EU-IMI consortia involving multiple industry partners (see biomap-imi.eu and hippocrates-imi.eu for details). F.C. has received grant support and consultancy fees from Boehringer Ingelheim. S.K.M. reports departmental income from Abbvie, Almirall, Eli Lilly, Leo, Novartis, Sanofi, UCB, outside the submitted work. The remaining authors declare no competing interests.
